Thus, both nivolumab plus ipilimumab (N‐I) and PEM monotherapy were recommended as chemotherapy‐free 1L treatment for PD‐L1‐positive NSCLC by the recently published National Comprehensive Cancer Network Clinical Practice Guidelines.5 The gene discussed is CD274; the disease is non-small cell lung carcinoma.